Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) Director Gregg Williams purchased 48,100 shares of the stock in a transaction that occurred on Friday, November 13th. The shares were bought at an average cost of $0.99 per share, for a total transaction of $47,619.00. Following the acquisition, the director owned 36,960,836 shares of the company’s stock, valued at approximately $36,591,227.64. The trade was a 0.13% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Vivani Medical Price Performance
Shares of VANI stock opened at $1.01 on Monday. The stock’s 50-day moving average price is $1.18 and its 200 day moving average price is $1.24. The stock has a market capitalization of $91.11 million, a PE ratio of -3.16 and a beta of 2.51. Vivani Medical, Inc. has a 52-week low of $0.80 and a 52-week high of $1.66.
Vivani Medical (NASDAQ:VANI – Get Free Report) last posted its quarterly earnings data on Wednesday, November 11th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, October 2nd. Wall Street Zen lowered shares of Vivani Medical from a “hold” rating to a “sell” rating in a research report on Sunday. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $3.75.
Get Our Latest Analysis on Vivani Medical
Vivani Medical Company Profile
Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.
See Also
- Five stocks we like better than Vivani Medical
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
